AU2014329513A1 - Therapy with cells from human placenta and hematopoietic cells - Google Patents
Therapy with cells from human placenta and hematopoietic cells Download PDFInfo
- Publication number
- AU2014329513A1 AU2014329513A1 AU2014329513A AU2014329513A AU2014329513A1 AU 2014329513 A1 AU2014329513 A1 AU 2014329513A1 AU 2014329513 A AU2014329513 A AU 2014329513A AU 2014329513 A AU2014329513 A AU 2014329513A AU 2014329513 A1 AU2014329513 A1 AU 2014329513A1
- Authority
- AU
- Australia
- Prior art keywords
- cells
- ucb
- subject
- placental perfusate
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 title claims abstract description 28
- 210000004027 cell Anatomy 0.000 title claims description 481
- 210000002826 placenta Anatomy 0.000 title claims description 75
- 238000002560 therapeutic procedure Methods 0.000 title description 11
- 230000003169 placental effect Effects 0.000 claims abstract description 183
- 238000000034 method Methods 0.000 claims abstract description 132
- 206010068051 Chimerism Diseases 0.000 claims abstract description 43
- 210000005087 mononuclear cell Anatomy 0.000 claims abstract description 42
- 208000009329 Graft vs Host Disease Diseases 0.000 claims abstract description 20
- 208000024908 graft versus host disease Diseases 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 208000024891 symptom Diseases 0.000 claims abstract description 12
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 10
- 208000019838 Blood disease Diseases 0.000 claims abstract description 8
- 208000014951 hematologic disease Diseases 0.000 claims abstract description 8
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims abstract description 7
- 210000004700 fetal blood Anatomy 0.000 claims description 353
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 19
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 14
- 210000005259 peripheral blood Anatomy 0.000 claims description 13
- 239000011886 peripheral blood Substances 0.000 claims description 13
- 210000001185 bone marrow Anatomy 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 7
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 7
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims description 7
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 7
- 201000005787 hematologic cancer Diseases 0.000 claims description 6
- 230000036210 malignancy Effects 0.000 claims description 6
- 210000002449 bone cell Anatomy 0.000 claims description 5
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 5
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 208000007056 sickle cell anemia Diseases 0.000 claims description 4
- 102100033051 40S ribosomal protein S19 Human genes 0.000 claims description 3
- 208000031277 Amaurotic familial idiocy Diseases 0.000 claims description 3
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 claims description 3
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 claims description 3
- 208000015872 Gaucher disease Diseases 0.000 claims description 3
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 3
- 208000028226 Krabbe disease Diseases 0.000 claims description 3
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims description 3
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims description 3
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 3
- 208000026589 Wolman disease Diseases 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 208000005980 beta thalassemia Diseases 0.000 claims description 3
- 201000008049 fucosidosis Diseases 0.000 claims description 3
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 claims description 3
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims description 3
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 claims description 3
- 208000002491 severe combined immunodeficiency Diseases 0.000 claims description 3
- 206010043554 thrombocytopenia Diseases 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 25
- 210000004369 blood Anatomy 0.000 abstract description 23
- 239000000203 mixture Substances 0.000 abstract description 14
- 230000010412 perfusion Effects 0.000 description 39
- 210000003954 umbilical cord Anatomy 0.000 description 32
- 230000037396 body weight Effects 0.000 description 26
- 239000012530 fluid Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 14
- 230000003750 conditioning effect Effects 0.000 description 11
- 210000000440 neutrophil Anatomy 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 210000003606 umbilical vein Anatomy 0.000 description 10
- 230000036266 weeks of gestation Effects 0.000 description 10
- 210000000130 stem cell Anatomy 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 9
- 230000003211 malignant effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 108091092878 Microsatellite Proteins 0.000 description 6
- 208000035010 Term birth Diseases 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 210000001644 umbilical artery Anatomy 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 229940127219 anticoagulant drug Drugs 0.000 description 5
- 208000005107 Premature Birth Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010015719 Exsanguination Diseases 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001400 myeloablative effect Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000001126 phototherapy Methods 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- KYITYFHKDODNCQ-UHFFFAOYSA-M sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [Na+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 KYITYFHKDODNCQ-UHFFFAOYSA-M 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 229960002647 warfarin sodium Drugs 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000270728 Alligator Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010062018 Inborn error of metabolism Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 208000022806 beta-thalassemia major Diseases 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- -1 e.g. Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000000998 lymphohematopoietic effect Effects 0.000 description 1
- 210000004993 mammalian placenta Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020202076A AU2020202076A1 (en) | 2013-10-03 | 2020-03-23 | Therapy with cells from human placenta and hematopoietic cells |
| AU2022215207A AU2022215207A1 (en) | 2013-10-03 | 2022-08-10 | Therapy with cells from human placenta and hematopoietic cells |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361886648P | 2013-10-03 | 2013-10-03 | |
| US61/886,648 | 2013-10-03 | ||
| US201361890057P | 2013-10-11 | 2013-10-11 | |
| US61/890,057 | 2013-10-11 | ||
| PCT/US2014/058774 WO2015051088A1 (en) | 2013-10-03 | 2014-10-02 | Therapy with cells from human placenta and hematopoietic cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020202076A Division AU2020202076A1 (en) | 2013-10-03 | 2020-03-23 | Therapy with cells from human placenta and hematopoietic cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2014329513A1 true AU2014329513A1 (en) | 2016-04-28 |
Family
ID=52779130
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014329513A Abandoned AU2014329513A1 (en) | 2013-10-03 | 2014-10-02 | Therapy with cells from human placenta and hematopoietic cells |
| AU2020202076A Abandoned AU2020202076A1 (en) | 2013-10-03 | 2020-03-23 | Therapy with cells from human placenta and hematopoietic cells |
| AU2022215207A Abandoned AU2022215207A1 (en) | 2013-10-03 | 2022-08-10 | Therapy with cells from human placenta and hematopoietic cells |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020202076A Abandoned AU2020202076A1 (en) | 2013-10-03 | 2020-03-23 | Therapy with cells from human placenta and hematopoietic cells |
| AU2022215207A Abandoned AU2022215207A1 (en) | 2013-10-03 | 2022-08-10 | Therapy with cells from human placenta and hematopoietic cells |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10179152B2 (enExample) |
| EP (1) | EP3052109B8 (enExample) |
| JP (4) | JP2016531889A (enExample) |
| KR (3) | KR20160102965A (enExample) |
| CN (1) | CN105792834A (enExample) |
| AU (3) | AU2014329513A1 (enExample) |
| CA (1) | CA2926199C (enExample) |
| DK (1) | DK3052109T3 (enExample) |
| MX (2) | MX2016004209A (enExample) |
| RU (2) | RU2019131152A (enExample) |
| WO (1) | WO2015051088A1 (enExample) |
| ZA (1) | ZA201602151B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10456423B2 (en) | 2016-06-13 | 2019-10-29 | SMART SURGICAL, Inc. | Compositions for biological systems and methods for preparing and using the same |
| US10426796B2 (en) | 2016-06-13 | 2019-10-01 | SMART SURGICAL, Inc. | Compositions for biological systems and methods for preparing and using the same |
| US11285177B2 (en) | 2018-01-03 | 2022-03-29 | Globus Medical, Inc. | Allografts containing viable cells and methods thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5437994A (en) * | 1989-06-15 | 1995-08-01 | Regents Of The University Of Michigan | Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
| IL107483A0 (en) * | 1993-11-03 | 1994-02-27 | Yeda Res & Dev | Bone marrow transplantation |
| JP2004528021A (ja) * | 2001-02-14 | 2004-09-16 | アンスロジェネシス コーポレーション | 分娩後の哺乳動物の胎盤、その使用およびそれに由来する胎盤幹細胞 |
| AU2004212009B2 (en) * | 2003-02-13 | 2010-07-29 | Celularity Inc. | Use of umbilical cord blood to treat individuals having a disease, disorder or condition |
| AU2006332679A1 (en) * | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
| EP1987135A2 (en) * | 2006-01-27 | 2008-11-05 | Auxocell Laboratories, Inc. | Methods and compositions relating to stem cell transplantation |
| CN105087490A (zh) * | 2006-05-11 | 2015-11-25 | 脐血科技公司 | 收集和使用胎盘脐血干细胞的方法 |
| CA2700617C (en) * | 2007-09-28 | 2018-11-06 | Celgene Cellular Therapeutics | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
-
2014
- 2014-10-02 EP EP14850630.6A patent/EP3052109B8/en active Active
- 2014-10-02 RU RU2019131152A patent/RU2019131152A/ru unknown
- 2014-10-02 MX MX2016004209A patent/MX2016004209A/es unknown
- 2014-10-02 KR KR1020167011298A patent/KR20160102965A/ko not_active Ceased
- 2014-10-02 US US15/026,896 patent/US10179152B2/en active Active
- 2014-10-02 CN CN201480066174.6A patent/CN105792834A/zh active Pending
- 2014-10-02 AU AU2014329513A patent/AU2014329513A1/en not_active Abandoned
- 2014-10-02 KR KR1020227010134A patent/KR20220044384A/ko not_active Ceased
- 2014-10-02 KR KR1020217013395A patent/KR20210054046A/ko not_active Ceased
- 2014-10-02 JP JP2016519848A patent/JP2016531889A/ja active Pending
- 2014-10-02 WO PCT/US2014/058774 patent/WO2015051088A1/en not_active Ceased
- 2014-10-02 RU RU2016116816A patent/RU2016116816A/ru unknown
- 2014-10-02 DK DK14850630.6T patent/DK3052109T3/da active
- 2014-10-02 CA CA2926199A patent/CA2926199C/en active Active
-
2016
- 2016-03-31 ZA ZA2016/02151A patent/ZA201602151B/en unknown
- 2016-04-01 MX MX2021003798A patent/MX2021003798A/es unknown
-
2019
- 2019-06-18 JP JP2019112450A patent/JP2019194211A/ja not_active Withdrawn
-
2020
- 2020-03-23 AU AU2020202076A patent/AU2020202076A1/en not_active Abandoned
-
2021
- 2021-04-07 JP JP2021065060A patent/JP2021107407A/ja not_active Withdrawn
-
2022
- 2022-08-10 AU AU2022215207A patent/AU2022215207A1/en not_active Abandoned
-
2023
- 2023-02-27 JP JP2023027978A patent/JP2023078156A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10179152B2 (en) | 2019-01-15 |
| CA2926199C (en) | 2022-05-17 |
| EP3052109A4 (en) | 2017-05-03 |
| KR20220044384A (ko) | 2022-04-07 |
| WO2015051088A1 (en) | 2015-04-09 |
| ZA201602151B (en) | 2022-12-21 |
| KR20160102965A (ko) | 2016-08-31 |
| JP2023078156A (ja) | 2023-06-06 |
| KR20210054046A (ko) | 2021-05-12 |
| MX2016004209A (es) | 2016-07-11 |
| JP2016531889A (ja) | 2016-10-13 |
| EP3052109B1 (en) | 2021-05-12 |
| DK3052109T3 (da) | 2021-08-16 |
| US20160235790A1 (en) | 2016-08-18 |
| RU2019131152A3 (enExample) | 2022-02-24 |
| EP3052109A1 (en) | 2016-08-10 |
| MX2021003798A (es) | 2021-05-27 |
| EP3052109B8 (en) | 2021-06-23 |
| JP2019194211A (ja) | 2019-11-07 |
| NZ718571A (en) | 2023-12-22 |
| CN105792834A (zh) | 2016-07-20 |
| RU2016116816A (ru) | 2017-11-13 |
| RU2019131152A (ru) | 2019-11-11 |
| RU2016116816A3 (enExample) | 2018-08-02 |
| CA2926199A1 (en) | 2015-04-09 |
| AU2022215207A1 (en) | 2022-09-01 |
| JP2021107407A (ja) | 2021-07-29 |
| AU2020202076A1 (en) | 2020-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022215207A1 (en) | Therapy with cells from human placenta and hematopoietic cells | |
| DK2217329T3 (en) | APPLICATION OF NAVLINE BLOOD IN THE TREATMENT OF COMPLIANCES IN CONNECTION WITH PREGNANCY BIRTH | |
| Barker et al. | A “no-wash” albumin-dextran dilution strategy for cord blood unit thaw: high rate of engraftment and a low incidence of serious infusion reactions | |
| Broxmeyer et al. | Cord blood hematopoietic cell transplantation | |
| Elchalal et al. | Postpartum umbilical cord blood collection for transplantation: a comparison of three methods | |
| Teare et al. | Is cell salvaged vaginal blood loss suitable for re-infusion? | |
| Lew et al. | Implementation of an obstetric cell salvage service in a tertiary women’s hospital | |
| Storb et al. | Rejection of marrow from DLA-identical canine littermates given transfusions before grafting: antigens involved are expressed on leukocytes and skin epithelial cells but not on platelets and red blood cells | |
| Sreelakshmi et al. | Acute hypotension associated with leucocyte depletion filters during cell salvaged blood transfusion | |
| Dhot et al. | Cord blood stem cell banking and transplantation | |
| Sivakumaran et al. | Umbilical cord blood banking and its therapeutic uses | |
| HK1227309B (en) | Therapy with cells from human placenta and hematopoietic cells | |
| HK1227309A1 (en) | Therapy with cells from human placenta and hematopoietic cells | |
| Cappell | The significance of the Rh factor in medicine and obstetrics | |
| Quigley et al. | Non immune hydrops due to parvovirus B19 in pregnancy: a case report | |
| Katzenstein et al. | Haploidentical related umbilical cord blood stem cell transplant in a child with acute non-lymphocytic leukemia | |
| WO2015164233A1 (en) | Treatment of conditions and complications in infants | |
| CN104721232A (zh) | 脐带血免疫细胞在制备治疗银屑病药物中的应用 | |
| Pfalzgraf et al. | Autotransfusion in obstetrics: a narrative review | |
| Eze et al. | Umbilical Cord Blood Collection Protocol and the Impact on the Nucleated and Progenitor Cell Quantity and Quality | |
| Norville et al. | Hematopoietic stem cell transplantation | |
| Dasari et al. | Prevention of transfusion reactions and in post transfusion reactions, promoting patient safety [3P’s] | |
| CN114466655A (zh) | 心血管疾病的治疗 | |
| Losee | Blood transfusion in obstetrics | |
| Ferguson et al. | and Manipulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: CELULARITY, INC. Free format text: FORMER APPLICANT(S): ANTHROGENESIS CORPORATION |
|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |